The industry's own research.
112 reports
showing 61–112 of 112
This is a market report published by CBRE in December 2025 providing an overview of the San Diego life sciences sector for the fourth quarter of 2025. The report covers the life sciences market in San Diego, California, with references to national context.
This is a quarterly market data report published by CBRE in March 2026 covering the life sciences sector in the Boston metropolitan area.
The SF Bay Area Life Sciences MarketBeat Q1 2026 report covers the region's life sciences real estate market, documenting 113,700 employed positions, a 28.5% overall vacancy rate, asking rents of $5.71 per square foot, and $1.4 billion in venture capital funding during the first quarter. Key findings include eight large-scale projects totaling approximately 2.0 million square feet completed in 2025, overall leasing activity of 664,755 square feet in Q1 2026, and projections that sublease availability will increase while venture capital funding remains critical to market recovery.
The San Francisco Bay Area life science market recorded negative net absorption of 453,685 square feet in Q1 2026, with overall vacancy rising to 29.0% and total availability at 32.3%, while major transactions included Gladstone Institutes' 108,082-square-foot lease and the $600 million sale of Gateway Commons campus. Life science employment declined 7.6% from its 2023 peak to 107,610 workers in Q3 2025, venture capital funding fell to $1.7 billion across 79 deals in Q1 (down from $2.7 billion and 92 deals in Q4), and average asking rents decreased to $5.57 per square foot as the market contended with elevated vacancy and soft leasing conditions.
JLL's 2026 EMEA edition: laboratory space remains a niche asset class with concentrated demand; AI creating cross-industry occupancy opportunities and reshaping facility requirements.
Quarterly Golden Triangle (Oxford, Cambridge, London) take-up, lab supply, rents and VC trends; covers LSIMF government grant programme and AstraZeneca investment.
CBRE quarterly figures across the top 13 US life sciences markets: vacancy, absorption, rental rates and employment data for lab/R&D space.
Global lab/cGMP rents down 1.7% YoY as vacancy reached 23.1%; R&D investment sales rebounded to $13.5B in 2025, up 28% YoY.
Newmark's Q4 2025 US life science report: national vacancy declined for the first time in over a year as the sector reached the bottom of its correction cycle.
Quarterly Washington DC metro life sciences market report covering vacancy, leasing, rents and supply.
Colliers' forward outlook for US life sciences real estate, covering supply absorption, demand drivers, and market recalibration heading into 2026.
NYC life sciences vacancy declined modestly to 31.8% (from 33.7% in Q4 2024); over a quarter of inventory remains vacant.
C&W's national life sciences MarketBeat: full-year 2025 sales volume of $9.8B (+39% YoY), vacancy and rent trends, and a shrinking construction pipeline.
.jpg)
Chicago Q4 2025 life sciences market report on lab vacancy, leasing and rents in an emerging cluster.
.jpg)
Boston-Cambridge vacancy up 860 bps YoY to 25.5%; 4.4M sq ft under construction, down from 8.3M a year earlier as the pipeline decelerates.
.jpg)
Seattle Q4 2025 life sciences market report tracking lab vacancy, leasing activity and rent trends.
.jpg)
San Diego vacancy up 61.6% YoY to 28.6%, driven by delivery of 3M+ sq ft of new life sciences space.
CBRE's 2026 outlook chapter: lab/R&D vacancy expected to stabilize at a cyclical peak of 23.3% as new supply dwindles and capital re-engages; construction near a 10-year low.
Q3 2025 US life science conditions: early stabilization as leasing and tenant demand modestly improved across Boston, San Diego and the Bay Area.
Analysis of medical outpatient and life sciences transaction activity in H1 2025; MOB transaction volume reached $2.8B in Q3 2025 amid awaited rate cuts.
CBRE quarterly data note on US lab/R&D vacancy, absorption, leasing and venture funding for Q3 2025.
Q3 2025 US life sciences data: 24.7% vacancy, $66.35 psf asking rent (-4.4% YoY), and -1.3M sq ft net absorption.
Quarterly Greater Boston lab market metrics covering vacancy, absorption, rents and the construction pipeline.
24-page PDF ranking US life science clusters across AI, startups, biomanufacturing, talent and medtech; forecasts availability falling toward 20% by 2030.
JLL's flagship US life sciences outlook: 61M sq ft of available lab space, ~27% vacancy, and how AI-native biotechs (one-sixth of biotech VC deals) reshape lab demand across major clusters.
Greater Boston life sciences vacancy at a record 33.9% while H1 2025 leasing surged to 95.6% of 2024's full-year total, led by Biogen's 585,000 sq ft Cambridge HQ deal.
Ranks 43 European life sciences clusters across themes including digital health R&D and pharma manufacturing; covers VC flows, AI impact, sustainability, and new lab supply.
CBRE talent trends: US life sciences employment hit a record 2.1M in March 2025; Boston-Cambridge and SF Bay Area lead talent rankings. Substantial data shown free on page.
JLL's June 2025 US Life Sciences Property Report PDF covering six trends in current lab market dynamics across the major US clusters.
Knight Frank examines biotech growth and UK property demand, urging investors to focus on knowledge-dense clusters (Cambridge, Oxford, London) and flexible, future-proofed facilities.
Newmark's Q1 2025 US life science market perspectives covering vacancy, leasing, venture funding and capital-markets liquidity.
Knight Frank's UK life sciences research, tracking biotech company growth (15,436 UK firms, +22% since 2019) and lab supply across the golden triangle.
CBRE global atlas of life sciences clusters and real estate fundamentals across major innovation hubs worldwide.
.jpg)
Bay Area Q1 2025 life sciences market: vacancy, leasing and rent trends across the region's lab clusters.
Savills Australia life sciences trends and outlook, covering demand drivers, lab/R&D supply and investment across Australian markets.
San Diego Q1 2025 life sciences report tracking vacancy, leasing and rents in a softening lab market.
Nearly half of tracked US life sciences markets saw negative net absorption, but biotech R&D employment rose 3%+ in 2024 to an all-time high; long-term fundamentals remain strong.
CBRE annual US life sciences outlook: Q4 lab leasing up 28% YoY, positive net absorption, ~8M sq ft of new lab space due in 2025, rising concessions in Boston and the Bay Area.
Knight Frank's UK science & innovation insight PDF: golden-triangle lab availability up 68% YoY to 1.2M sq ft with 3.65M sq ft under construction through 2028.
CBRE's European life sciences ecosystems report PDF (9.3MB): lab space commands rent premiums over office; 43 of top-100 life sciences universities are in Europe; growing investor interest.
JLL on UK life sciences real estate investment stabilizing after a 2023 dip; equity and debt investors more comfortable backing the sector amid purpose-built lab undersupply in the Golden Triangle.
Clarion Partners research thesis on healthcare real estate (life sciences, medical, seniors housing) positioned for long-term growth from aging demographics and rising healthcare spend.
Nuveen Real Estate (with ULI) on the Asia Pacific life sciences sector: drivers of successful locations, company space requirements and investment characteristics for the asset class.
Principal's mid-year house view argues the CRE recovery remains intact but uneven, with high conviction in data centers and residential, caution on life sciences, and an increasingly global portfolio approach.
Newmark presents the second quarter 2025 U.S. Life Science Market Conditions & Trends report, tracking leasing, lab demand, vacancy and tenant activity across major life science clusters.
Barings discusses emerging demand drivers and underwriting approaches for alternative real estate sectors and the case for diversification beyond the core property types.
The report tracks U.S. life sciences lab and research space demand, supply and rents across the major hubs. It assesses fundamentals amid shifting venture capital funding.
JLL reports the U.S. lab market now exceeds 200 million square feet with a supply-to-demand ratio near 6 to 1, as AI and tough-tech firms take a growing share of leasing, including 30% of Boston signings in 2025.
Clarion Partners sizes the U.S. commercial real estate investable universe across property types and strategies. The report quantifies the opportunity set available to institutional investors.
The GREFI All Funds Index, produced with INREV and NCREIF, was positive for the fifth consecutive quarter in Q3 2025 with a total return of 0.89 percent, down 13 basis points from 1.02 percent in Q2 2025. All regions recorded positive returns, with Asia Pacific leading, and core funds outperformed non-core peers.
Hines' flagship annual outlook argues global real estate stabilizes and enters a new growth cycle, offering institutional investors strategic analysis of cross-sector and cross-market opportunities for 2026.
.png)
Life sciences venture capital funding reached 20.8 billion dollars in the first half of 2025, equal to 44.9 percent of the 2024 total. High rents in Boston-Cambridge, the Bay Area and San Diego pushed companies toward lower-cost markets.